Back to top
more

Erytech Pharma SA Sponsored ADR (ERYP)

(Delayed Data from NSDQ)

$5.80 USD

5.80
3,129

+0.10 (1.75%)

Updated Sep 25, 2020 01:41 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (192 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for ERYP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Erytech Pharma SA Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 82 159 210 42 NA
Receivables 0 0 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 2 0 0 NA
Other Current Assets 9 17 7 5 NA
Total Current Assets 91 177 217 47 NA
Net Property & Equipment 29 18 4 2 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 1 2 0 0 NA
Deposits & Other Assets 12 1 0 0 NA
Total Assets 133 198 221 50 NA
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 0 NA
Accounts Payable 15 20 9 5 NA
Current Portion Long-Term Debt 0 1 1 0 NA
Current Portion Capital Leases 2 0 0 0 NA
Accrued Expenses 0 0 0 0 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 5 4 3 2 NA
Total Current Liabilities 22 24 13 7 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 1 1 2 3 NA
Non-Current Capital Leases 13 0 0 0 NA
Other Non-Current Liabilities 1 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 37 26 16 10 NA
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 2 2 2 1 NA
Capital Surplus 315 333 318 116 NA
Retained Earnings -70 -45 -38 -24 NA
Other Equity -152 -118 -78 -54 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 96 172 205 39 NA
Total Liabilities & Shareholder's Equity 133 198 221 50 NA
Total Common Equity 96 172 205 39 0
Shares Outstanding 17.90 17.90 17.10 NA NA
Book Value Per Share 5.35 9.61 11.99 0.00 0.00

Fiscal Year End for Erytech Pharma SA Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Assets          
Cash & Equivalents NA NA 82 91 106
Receivables NA NA 0 0 1
Notes Receivable NA NA 0 0 NA
Inventories NA NA 0 0 0
Other Current Assets NA NA 9 16 17
Total Current Assets NA NA 91 108 124
Net Property & Equipment NA NA 29 30 29
Investments & Advances NA NA 0 0 NA
Other Non-Current Assets NA NA 0 0 NA
Deferred Charges NA NA 0 0 NA
Intangibles NA NA 1 2 2
Deposits & Other Assets NA NA 12 1 8
Total Assets NA NA 133 152 164
Liabilities & Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Notes Payable NA NA 0 0 NA
Accounts Payable NA NA 15 14 13
Current Portion Long-Term Debt NA NA 0 0 0
Current Portion Capital Leases NA NA 2 1 1
Accrued Expenses NA NA 0 0 NA
Income Taxes Payable NA NA 0 0 NA
Other Current Liabilities NA NA 5 5 7
Total Current Liabilities NA NA 22 21 21
Mortgages NA NA 0 0 NA
Deferred Taxes/Income NA NA 0 0 NA
Convertible Debt NA NA 0 0 NA
Long-Term Debt NA NA 1 1 1
Non-Current Capital Leases NA NA 13 13 9
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA NA 0 0 NA
Total Liabilities NA NA 37 36 32
Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Preferred Stock NA NA 0 0 NA
Common Stock (Par) NA NA 2 2 2
Capital Surplus NA NA 315 313 317
Retained Earnings NA NA -70 -48 -33
Other Equity NA NA -152 -151 -154
Treasury Stock NA NA 0 0 NA
Total Shareholder's Equity NA NA 96 116 132
Total Liabilities & Shareholder's Equity NA NA 133 152 164
Total Common Equity 0 0 96 116 100,131
Shares Outstanding 17.90 17.90 17.90 17.90 17.90
Book Value Per Share 0.00 0.00 5.35 6.47 5,593.88